|
Bremelanotide; PT-141
Cas No.: 32780-32-8
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.2
Molecular Structure:
Purity (HPLC): 98.0%min.
Single Impurity (HPLC): 1.0%max
Amino Acid Composition: about 10% of theoretical
Peptide Content (N%): 80.0% min.
Water Content(Karl Fischer): 6.0%max.
Acetate Content (HPIC): 15.0%max.
MS(ESI): Consistent
Mass Balance: 95.0~105.0%
Appearance: White powder
Payment: Bank Transfer, ,
Express: EMS, DHL, FedEx, etc(door-to-door)
Delivery: Safe & timely, around 1-3 days after payment
Description
Scientists have developed a drug that could boost female sexual desire. Tests in female rats are provingpromising, showing "significantly enhanced" sexual behaviour. Its developers believe it could be a more
significant development in the treatment of sexual dysfunction.If human trials do prove successful, it could be on the market within three years.
The drug, PT141, is being developed by researchers at Concordia University, Montreal, Canada and Palatin
Technologies - the company which is developing it. PT141 seems to encourage the female rats to actively
seek out the males for sex, which in turn heightens their sexual arousal.
The drug, which comes in the form of a nasal spray, has a virtually instantaneous effect. The company iscarrying out tests to see if the drug benefits women who have normal sexual function.
A study involving men with erectile dysfunction is also underway. Experts in the UK stress research into the
drug is still at a very early stage, but say it is hopeful. Currently, the only help available for women with sexual dysfunction problems is psychological or sexual therapy.
Promising
PT141 is a copy of a hormone which has an effect on the nervous system called alpha-melanocyte-stimulating
hormone. It has been established that melanocyte-receptors in the brain play a part in several behaviours
including sexual arousal. So stimulating these receptors using PT141 may stimulate sexual function.
A study of around 40 female rats showed a three- to five-fold increase in solicitations in rats who were given the drug compared to those which were not.
Jim Pfaus, professor of psychology at Concordia University, is carrying out the research into PT141's effectson female rats, and he told BBC News Online: "There's nothing in the arsenal now to treat female sexual dysfunction. That's one of the things that's really promising about this drug".
"If you have a woman in a loving relationship, but who just doesn't feel desire for sex, the question is why.What goes on to inhibit that?"
He said it could be that there was an interruption in the "chain of command" within the body which leads to desiring sex.
Potential benefits
PT-141 in Men:
• effective in a broad range of patients, including those with severe ED and those non-responsive to sildenafil
• efficacy in “at-home” studies is comparable to PDE-5 inhibitors
• up to 50% of ED patients were restored to a normal level of function
• co-administration with sildenafil shows superior efficacy
• side effects include facial flushing, nausea, aftertaste and post-nasal drip
PT-141 in Women:
Palatin conducted a Phase 2A study in 18 premenopausal women with a diagnosis of female sexual
dysfunction (FSD). Patients reported a significant increase in sexual desire and in genital arousal after
receiving PT-141, compared to
placebo. Additionally, there was a correlation between sexual desire and genital arousal in patients receiving
PT-141, an observation that further reinforces the potential importance of these reports.
|
